Clinical Research Directory
Browse clinical research sites, groups, and studies.
This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SSGJ-626 in Participants With Active Cutaneous Lupus Erythematosus
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-11
Completion Date
2029-08
Last Updated
2026-10-28
Healthy Volunteers
No
Conditions
Interventions
Placebo
Placebo subcutaneous (SC) injection
Locations (2)
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College.
Nanjing, Jiangsusheng, China
Peking University First Hospital
Beijing, China